Dynamic competition in pharmaceuticals: Cross-national evidence from new drug diffusion

Managerial and Decision Economics

Volumn 28, Issue 4-5, 2007, Pages 231-250

  Berndt, Ernst R ^a   Danzon, Patricia M ^b,c   Kruse, Gregory B ^c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548295786     PISSN: 01436570     EISSN: 10991468     Source Type: Journal    
DOI: 10.1002/mde.1338     Document Type: Article

References (38)

1. Berndt ER, Bui LT, Lucking-Reiley DH, Urban GL. 1997. The roles of marketing, product quality, and price competition in the growth and composition of the U.S. antiulcer drug industry. In The Economics of New Goods, Bresnahan TF, Gordon RJ (eds). University of Chicago Press for the National Bureau of Economic Research: Chicago, 277-322.
2. Berndt ER, Bui LT, Lucking-Reiley DH, Urban GL. 1995. Information, marketing and pricing in the U.S. antiulcer drug market. American Economic Review 85(2): 100-105.
3. Berndt ER, Pindyck RS, Azoulay P. 2003. Consumption externalities and diffusion in pharmaceutical markets: antiulcer drugs. Journal of Industrial Economics 51(2): 243-270.
4. Brekke KR, Kuhn M. 2005. Direct to consumer advertising in pharmaceutical markets. CESifo Working Paper No. 1493, July. Available from http://SSRN.com/abstract= 759452
5. Chintagunta PK, Desiraju R. 2005. Strategic pricing and detailing behavior in international markets. Marketing Science 24(1): 67-80.
6. Coleman J, Katz E, Menzel H. 1966. Medical Innovation: A Diffusion Study. Bobbs-Merrill: Indianapolis, IN.
7. Comanor WS. 1964. Research and competitive product differentiation in the pharmaceutical industry in the United States. Economica, New Series 31(124): 372-384.
8. Danzon PM. 1999. Price Comparisons for Pharmaceuticals: A Review of U.S. and Cross-National Studies. AEI Press for the American Enterprise Institute: Washington, DC.
9. Danzon PM, Chao LW. Cross-national price differences for pharmaceuticals: how large and why? Journal of Health Economics 19(2): 159-195.
10. Danzon PM, Furukawa MP. 2003. Prices and availability of pharmaceuticals: evidence from nine countries. Health Affairs-Web Exclusive 22: W521-W536.
11. Danzon PM, Towse A. 2003. Differential pricing for pharmaceutical: reconciling access, R&D, and patents. International Journal of Health Care Finance and Economics 3: 183-205.
12. Danzon PM, Wang YR, Wang L. 2005. The impact of price regulation on the launch delay of new drugs. Journal of Health Economics 14(3): 269-292.
13. Deaton A, Muellbauer JM. 1980. An almost ideal demand system, American Economic Review 70(3): 312-326. (Forthcoming, International Journal of Research in Marketing.) Available at pradeep.chintagunta@gsb. uchicago.edu
14. Desiraju R. Nair H, Chintagunta P. 2004. Diffusion of new pharmaceutical drugs in developing and developed nations. International Journal of Research in Marketing 21: 341-347.
15. Farley JU, Lehmann DR. 1994. Cross-national laws and differences in market responses. Management Science 40(1): 111-122.
16. Fischer M, Clement M, Shankar V. 2005. Can a late mover use international market entry strategy to challenge the pioneer? Unpublished Working Paper, Texas A&M University, College Station, TX, April. Available from 〈vshankar@mays.tamu.edu〉
17. Freeh HE, Miller RD. 2004. The effects of pharmaceutical consumption and obesity on the quality of life in the Organization of Economic Cooperation and Development (OECD) countries. PharmacoEconomics 22(Suppl. 2): 25-36.
18. Geroski PA. 2000. Models of technology diffusion. Research Policy 29: 603-625.
19. IMS Health. 2002. Promotional Information Under the Microscope. IMS Health: Plymouth Meeting, PA.
20. Jang S-L, Dai S-C, Sung S. 2005. The pattern and externality effect of diffusion of mobile telecommunications: the case of the OECD and Taiwan. Information Economics and Policy 17: 133-148.
21. Lanjouw JO. 2005. Patents, price controls and access to new drugs: how policy affects global market entry. Working Paper, Agricultural and Resource Economics Department, University of California, Berkeley, CA. April 19.
22. Kalyanaram G, Robinson WT, Urban GL. 1995. Order of market entry: established empirical generalizations, emerging empirical generalizations, and future research. Marketing Science 14(3, Part 2): G212-G221.
23. Keller W. 2004. International technology diffusion. Journal of Economic Literature 42(3): 757-782.
24. Kyle M. 2004a. Pharmaceutical price controls and entry strategies. Fuqua School of Business, Duke University. Unpublished manuscript.
25. Kyle M. 2004b. The role of firm characteristics in pharmaceutical product launches. Fuqua School of Business, Duke University, Unpublished manuscript.
26. Lanjouw JO. 2005. Patents, price controls and access to new drugs: how policy affects global market entry. Unpublished manuscript, Agricultural and Resource Economics Department. University of CaliforniaBerkeley.
27. Leeflang PSH. Wittink RR. Wedel M. Naert PA. 2000. Building Models for Marketing Decisions. Kluwer: Norwell, MA.
28. Mizik N, Jacobson R. 2004. Are physicians 'easy marks'? Quantifying the effects of detailing and sampling on new prescriptions. Management Science 50(12): 1704-1715.
29. Mossialos E, Mrazek M, Walley T. 2004. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. Open University Press for the World Health Organization on behalf of the European Observatory on Health Systems and Policies: Berkshire, England.
30. Rizzo JA. 1990. Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs. Journal of Law and Economics 62(1): 89-116.
31. Sandberg B. 2002. Creating the market for disruptive innovation: market proactiveness at the launch stage. Journal of Targeting, Measurement and Analysis for Marketing 11(2): 184-196.
32. Schmalensee RL. 1982. Product differentiation advantages of pioneering brands. American Economic Review 72(3): 349-365.
33. Shankar V, Carpenter GS, Krishnamurthi L. 1998. Late mover advantage: how innovative late entrants outsell pioneers. Journal of Marketing Research 35: 54-70.
34. Skinner J, Staiger DL. 2005. Technology adoption from hybrid corn to beta blockers. Unpublished manuscript, Department of Economics, Dartmouth College, Hanover, NH.
35. Sorescu AB, Chandy RK, Prabhu JC. 2003. Sources and financial consequences of radical innovation: insights from pharmaceuticals. Journal of Marketing 67: 82-102.
36. Talukdar D, Sudhir K, Ainslie A. 2002. Investigating new product diffusion across products and countries. Marketing Science 21(1): 97-114.
37. Tellis GJ, Stremersch S, Yin E. 2003. The international takeoff of new products: the role of economics, culture and country innovativeness. Marketing Science 22(2): 188-208.
38. Telser LG, Best W, Egan JW, Higinbotham HN. 1975. The theory of supply with applications to the ethical pharmaceutical industry. Journal of Law and Economics 18(2): 449-478.